Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2011-01-11
2011-01-11
McIntosh, III, Traviss C (Department: 1623)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S001110
Reexamination Certificate
active
07868162
ABSTRACT:
The present invention provides protonated compounds having antiviral and antimicrobial activity. The invention also provides antimicrobial compositions comprising protonated compounds of the invention. The protonated compounds of the invention provide efficacious antimicrobial activity against resistant strains of bacteria and opportunistic fungi. The invention also provides antiviral compositions comprising compounds of the invention. Viruses that may be treated by compositions of the invention include, but are not limited to, HIV, HSV, CMV, HBV, HCV and influenza virus.
REFERENCES:
patent: 4105782 (1978-08-01), Yu et al.
patent: 4421769 (1983-12-01), Dixon et al.
patent: 4464392 (1984-08-01), Bailey et al.
patent: 4897355 (1990-01-01), Eppstein et al.
patent: 4908209 (1990-03-01), McIntosh, Jr. et al.
patent: 5030659 (1991-07-01), Bansemir et al.
patent: 5153000 (1992-10-01), Chikawa et al.
patent: 5153230 (1992-10-01), Jaffery
patent: 5294533 (1994-03-01), Lupski et al.
patent: 5360797 (1994-11-01), Johnson et al.
patent: 5420330 (1995-05-01), Brush
patent: 5510104 (1996-04-01), Allen
patent: 5603915 (1997-02-01), Nelson et al.
patent: 5652266 (1997-07-01), Bobier-Rival et al.
patent: 5739309 (1998-04-01), Dattagupta et al.
patent: 5747256 (1998-05-01), Yan et al.
patent: 5763468 (1998-06-01), Barranx et al.
patent: 5767054 (1998-06-01), Sprugel et al.
patent: 5830140 (1998-11-01), Dillinger et al.
patent: 5843998 (1998-12-01), Song et al.
patent: 6211162 (2001-04-01), Dale et al.
patent: 6211349 (2001-04-01), Dale et al.
patent: 6627215 (2003-09-01), Dale et al.
patent: 7176191 (2007-02-01), Dale et al.
patent: 2002/0032164 (2002-03-01), Dale et al.
patent: 2005/0025815 (2005-02-01), Dale et al.
patent: 2009/0092659 (2009-04-01), Dale et al.
patent: 0018492 (1980-11-01), None
patent: WO-89/01023 (1989-02-01), None
patent: WO-90/14074 (1990-11-01), None
patent: WO-91/16024 (1991-10-01), None
patent: WO-91/17424 (1991-11-01), None
patent: WO-94/08563 (1994-04-01), None
patent: WO-94/15619 (1994-07-01), None
patent: WO-96/29399 (1996-09-01), None
patent: WO-98/03533 (1998-01-01), None
patent: WO-98/23294 (1998-06-01), None
patent: WO-00/40591 (2000-07-01), None
patent: WO-00/57890 (2000-10-01), None
patent: WO-02/080668 (2002-10-01), None
patent: WO-02/089581 (2002-11-01), None
patent: WO-2008/133704 (2008-11-01), None
Dale et al., “Therapeutic Efficacy of Nubiotics against Burn Wound Infection byPseudomonas aeruginosa”, Antimicrobial agents and Chemotherapy, Aug. 2004, vol. 48, No. 8, pp. 2918-2923.
McCutcheon's, vol. 2 Functional Materials, North American Edition, 137-168 (1992).
Wenninger, et al., CTFA Cosmetic Ingredient Handbook, Second Edition, The Cosmetic, Toiletry and Fragrance Association, Washington, D.C., 572-575 and 580 (1992).
Archer et al.,Antimicrob. Agents Chemother. 38:2231-2237 (1994).
Bennett,Antisense Res. Devel. 3:235-241 (1993).
Burns et al., Advances in Pediatric Infectious Diseases 8:53-67 (1993).
Cameron, British Journal of Theatre Nursing 7(5):5-7 (Aug. 1997).
Cohen, Oligodeoxynucleotides;Antisense Inhibitors of Gene Expression, Boca Raton, FL, CRC Press. (1989).
Crooke, Antisense Nucleic Acid and Antisense RNA: Novel Pharmacological and Therapeutic Agents, B. Weiss ed., CRC Press Boca Raton, FL., p. 17 (1997).
Eck et al., Goodman & Gilman's The Pharmacological Basis of THerapeutics, Ninth Edition, McGraw-Hill, New York, p. 77-101 (1996).
Freelander, Hosp Med 59(6):484-487 (Jun. 1998).
Goth, Medical Pharmacology: Principles and Concepts, The C.V. Mosby Company, Saint Louis, MO..(1974).
Gould, et al.,Lancet, 22:1377-79 (1981).
Heidenreich et al.,Molecular Medicine Today, vol. 1(3):128-133 (1995).
Hoke et al.,Nucl. Acids Res. 19:5743 (1991).
Hughes et al.,Pharmaceutical Research12:817 (1995).
Jones et al.,Nurs Stand12(39):47-52 (Jun. 17-23, 1998).
Krieg et al.,Nature374:546-549 (1995).
Kristinsson,Microb. Drug Resistance1(2):121 (1995).
Levy et al.,J. Infect. Dis., 148:1069-1076 (1983).
Mastrangelo et al.,Seminars in Oncology, 23 (1):4-21 (Feb. 1996).
Pennington,Rev. Infect. Dis., 3:67-73 (1981).
Spotnitz et al.,Surg Clin North Am77(3):651-69 (Jun. 1997).
Staley et al.,Adv Wound Care10(2):39-44 (Mar.-Apr. 1997).
Ther Merck Index, 12th edition, pp. 1490-1491; 763-764 (1996).
Verma et al.,Nature, 389:239-242 (Sep. 1997).
Woodford et al.,J. Antimicrob. Chemother. 35:179-184 (1995).
Wu-Pong, S.,Pharmaceutical Technology, Oct., p. 102, 104, 106, 108, 110-112, 114 (1994).
Yamamoto et al.,Antisense Res. Devel. 4:119-122 (1994).
Zabransky et al.,J. Clin. Microbiol. 33(4):791-793 (1995).
Zimmer et al.,Biopolymers, 6(4):563-574 (1968).
Morbidity and Mortality Weekly Report, 45(6):121-144 (1996).
Reed et al., “A Simple Method of Estimating Fifty Percent Endpoints”Amer. J. Hyg., 27(3):493-497 (1938).
Snoeck, et al., “(S)-1-(3-Hydroxy-2-Phosphonylmethoxypropyl)Cytosine, a Potent and Selective Inhibitor of Human Cytomegalovirus Replication”,Antimicrobial Agents and Chemotherapy, 32(12):1839-1844 (1988).
T.W. Graham Solomans, Organic Chemistry, John Wiley and Sons, Inc., New York 6th ed. pp. 937-971 (Jul. 1998).
Beattie, Esq. Ingrid A.
Lakewood-Amedex, Inc.
McIntosh, III Traviss C
Mintz Levin Cohn Ferris Glovsky and Popeo P.C.
LandOfFree
Antimicrobial and antiviral compounds and methods for their use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antimicrobial and antiviral compounds and methods for their use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antimicrobial and antiviral compounds and methods for their use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2719945